Combination of gemcitabine,pegaspargase,etoposide,and dexamethasone(GPED)in treatment of advanced extranodal NK/T-cell lymphoma  

作　　者：Ruiying Fu Yuanzheng Liang Liqiang Wei Xindi Liu Yingshi Piao Liang Wang 

机构地区：[1]Department of Hematology,Beijing Tongren Hospital,Capital Medical University,Beijing 100730,China [2]Department of Pathology,Beijing Tongren Hospital,Capital Medical University,Beijing 100730,China [3]Beijing Key Laboratory of Head and Neck Molecular Diagnostic Pathology,Beijing Tongren Hospital,Capital Medical University,Beijing 100730,China

出　　处：《Chinese Medical Journal》2023年第6期732-734,共3页中华医学杂志（英文版）

基　　金：National Natural Science Foundation of China(No.82170181);Beijing Hospitals Authority Youth Programme(No.QML20200201);Beijing Natural Science Foundation(No.7222027);CSH Young Scholars and 3SBioPharmaceutical joint research project(No.KYC2201001)

摘　　要：To the Editor:Extranodal natural killer/T-cell lymphoma(ENKTCL)is a highly aggressive lymphoma,closely associated with Epstein–Barr virus(EBV)infection.By using the combination of radiotherapy(RT)and asparaginase-based chemotherapy,more than 70%of patients with early stage ENKTCL have been cured.[1]However,great challenges exist among patients at newly diagnosed advanced stage or relapsed/refractory ENKTCL.

关 键 词：LYMPHOMA chemotherapy EPSTEIN 

分 类 号：R733.1[医药卫生—肿瘤]